Published in Protein Sci on August 01, 1994
Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a anaphylatoxin receptor. J Exp Med (2001) 1.02
Identification of receptor-binding sites of monocyte chemotactic S19 ribosomal protein dimer. Am J Pathol (2001) 0.94
Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer. Nat Commun (2015) 0.91
Primary structure and functional characterization of rat C5a: an anaphylatoxin with unusually high potency. Protein Sci (1994) 0.83
Solution structure of a unique C5a semi-synthetic antagonist: implications in receptor binding. Protein Sci (1997) 0.81
The complement component C5 of the common carp (Cyprinus carpio): cDNA cloning of two distinct isotypes that differ in a functional site. Immunogenetics (2003) 0.80
Structural and functional characterization of human and murine C5a anaphylatoxins. Acta Crystallogr D Biol Crystallogr (2014) 0.77
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science (1990) 4.67
Additivity of mutational effects in proteins. Biochemistry (1990) 4.05
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Dissecting the catalytic triad of a serine protease. Nature (1988) 3.19
Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. Science (1989) 2.02
Human C5a and C5a analogs as probes of the neutrophil C5a receptor. Mol Immunol (1980) 1.41
Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation (1988) 1.39
Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc Natl Acad Sci U S A (1989) 1.26
Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor. J Immunol (1993) 1.21
Neutrophil-activating proteins in psoriasis. J Invest Dermatol (1992) 1.17
Chemical synthesis of a gene encoding the human complement fragment C5a and its expression in Escherichia coli. Proc Natl Acad Sci U S A (1985) 1.17
Activation of the complement system in the adult respiratory distress syndrome. Am Rev Respir Dis (1987) 1.12
Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data. Biochemistry (1989) 1.11
Neutrophil chemotactic factors in the respiratory tract of patients with chronic airway diseases or idiopathic pulmonary fibrosis. Am Rev Respir Dis (1992) 1.01
A mutation in the small (alpha) subunit of glycyl-tRNA synthetase affects amino acid activation and subunit association parameters. J Biol Chem (1990) 0.91
A direct in vivo comparison of the inflammatory properties of human C5a and C5a des Arg in human skin. J Immunol (1988) 0.89
Human C5a anaphylatoxin: gene synthesis, expression, and recovery of biologically active material from Escherichia coli. Methods Enzymol (1988) 0.88
Improvements in the minimum binding sequence of C5a: examination of His-67. J Med Chem (1992) 0.87
C5a structural requirements for neutrophil receptor interaction. Agents Actions Suppl (1991) 0.85
Site-specific mutations in the N-terminal region of human C5a that affect interactions of C5a with the neutrophil C5a receptor. Protein Sci (1993) 0.84
The significance of complement activation in the pathogenesis of hypersensitivity pneumonitis: sequential changes of complement components and chemotactic activities in bronchoalveolar lavage fluids. Int Arch Allergy Appl Immunol (1988) 0.83
Characterization of the binding of Bolton-Hunter labeled [125I]C5a to human neutrophil, monocyte and U-937 cell membranes. Mol Immunol (1992) 0.81
Complement activation products and factors influencing phagocyte migration in synovial fluids from children with chronic arthritis. Clin Exp Rheumatol (1986) 0.80
Fluorometer based multi-parameter analysis of phagocytic cell activation. Agents Actions (1987) 0.80
Structure-function studies in a series of carboxyl-terminal octapeptide analogues of anaphylatoxin C5a. J Med Chem (1992) 0.79
[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther (1989) 4.18
Transposon Tn554: complete nucleotide sequence and isolation of transposition-defective and antibiotic-sensitive mutants. EMBO J (1985) 3.68
The medium chain triglyceride diet and intractable epilepsy. Arch Dis Child (1986) 1.45
Analysis of hydroperoxide-induced tyrosyl radicals and lipoxygenase activity in aspirin-treated human prostaglandin H synthase-2. Biochemistry (1997) 1.44
Exudation primes human and guinea pig neutrophils for subsequent responsiveness to the chemotactic peptide N-formylmethionylleucylphenylalanine and increases complement component C3bi receptor expression. J Clin Invest (1986) 1.41
Induction of T cell activation by monoclonal anti-Thy-1 antibodies. J Immunol (1986) 1.30
Human neutrophil heterogeneity identified using flow microfluorometry to monitor membrane potential. J Clin Invest (1981) 1.26
Determination of selective and nonselective compounds for the 5-HT 1A and 5-HT 1B receptor subtypes in rat frontal cortex. J Pharmacol Exp Ther (1984) 1.15
Benzofuro[2,3-c]pyridin-6-ols: synthesis, affinity for opioid-receptor subtypes, and antinociceptive activity. J Med Chem (1989) 1.12
Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem (1991) 1.11
The intestinal fatty acid binding protein is not essential for dietary fat absorption in mice. FASEB J (2000) 1.11
Peptide-encoding for structure determination of nonsequenceable polymers within libraries synthesized and tested on solid-phase supports. Pept Res (1993) 1.07
Autoradiographic distribution of 125I-galanin binding sites in the rat central nervous system. Peptides (1987) 1.06
Molecular cloning and expression of the cDNAs encoding human and yeast mevalonate pyrophosphate decarboxylase. J Biol Chem (1996) 1.06
Mutational analysis of att554, the target of the site-specific transposon Tn554. Plasmid (1991) 1.01
Characterization of human PLD2 and the analysis of PLD isoform splice variants. FASEB J (1998) 1.00
Secretagogue modulation of the response of human neutrophils to chemoattractants: studies with a membrane potential sensitive cyanine dye. Mol Immunol (1980) 0.98
Bis(sulfato)-cyclosiphonodictyol A, a new disulfated sesquiterpene-hydroquinone from a deep water collection of the Marine sponge Siphonodictyon coralliphagum. J Nat Prod (1995) 0.98
One drug for childhood grand mal: medical audit for three-year remissions. Dev Med Child Neurol (1984) 0.93
One-bead-one-structure combinatorial libraries. Biopolymers (1995) 0.92
Organelle-depleted human neutrophil cytoplasts used to study fmet-leu-phe receptor modulation and cell function. J Immunol (1984) 0.91
Residues 21-30 within the extracellular N-terminal region of the C5a receptor represent a binding domain for the C5a anaphylatoxin. J Biol Chem (1998) 0.91
[3H]2-phenylaminoadenosine ([3H]CV 1808) labels a novel adenosine receptor in rat brain. J Pharmacol Exp Ther (1992) 0.90
Interaction of the D1 receptor antagonist SCH 23390 with the central 5-HT system: radioligand binding studies, measurements of biochemical parameters and effects on L-5-HTP syndrome. J Recept Res (1988) 0.90
Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist. Eur J Pharmacol (1987) 0.90
Microxine, a new cdc2 kinase inhibitor from the Australian marine sponge Microxina species. J Nat Prod (2001) 0.89
Differential binding of chemoattractant peptide to subpopulations of human neutrophils. J Immunol (1984) 0.89
Propanolol ('Inderal') in the treatment of childhood migraine. Dev Med Child Neurol (1984) 0.88
The novel anticonvulsant MK-801 interacts with central phencyclidine recognition sites in rat brain. Eur J Pharmacol (1987) 0.87
Polymorphonuclear leukocyte heterogeneity in neonates and adults. Blood (1986) 0.87
Isolation and structure elucidation of 34-sulfatobastadin 13, an inhibitor of the endothelin A receptor, from a marine sponge of the genus Ianthella. J Nat Prod (1993) 0.86
Role of octanoic and decanoic acids in the control of seizures. Arch Dis Child (1986) 0.86
Discriminatory roles for D1 and D2 dopamine receptor subtypes in the in vivo control of neostriatal cyclic GMP. Eur J Pharmacol (1990) 0.84
Characterization of rat lung endothelin receptor subtypes which are coupled to phosphoinositide hydrolysis. J Pharmacol Exp Ther (1992) 0.84
A high-density quantitative nuclease protection microarray platform for high throughput analysis of gene expression. J Biotechnol (2011) 0.84
Characterization of the binding of [3H]-CGS 19755: a novel N-methyl-D-aspartate antagonist with nanomolar affinity in rat brain. Br J Pharmacol (1988) 0.84
Development of tolerance to the antihypertensive effects of highly selective adenosine A2a agonists upon chronic administration. J Pharmacol Exp Ther (1993) 0.83
Iron deficiency alters discrete proteins in rat caudate nucleus and nucleus accumbens. J Neurochem (1986) 0.83
Measurement of the protein tyrosine kinase activity of c-src using time-resolved fluorometry of europium chelates. Anal Biochem (1996) 0.83
Inhibition of nigrostriatal release of dopamine in the rat by adenosine receptor agonists: A1 receptor mediation. Neuropharmacology (1989) 0.82
Modulation of in vivo dopamine release by D2 but not D1 receptor agonists and antagonists. J Neurochem (1987) 0.82
Development of selective tolerance to the serotonin behavioral syndrome and suppression of locomotor activity after repeated administration of either 5-MeODMT or mCPP. Life Sci (1985) 0.82
Characterization of the binding of Bolton-Hunter labeled [125I]C5a to human neutrophil, monocyte and U-937 cell membranes. Mol Immunol (1992) 0.81
Dopamine autoreceptors modulate the in vivo release of dopamine in the frontal, cingulate and entorhinal cortices. J Pharmacol Exp Ther (1987) 0.81
Solution structure of a unique C5a semi-synthetic antagonist: implications in receptor binding. Protein Sci (1997) 0.81
Biochemical characterization of the antagonist actions of the xanthines, PACPX (1,3-dipropyl-8(2-amino-4-chloro)phenylxanthine) and 8-PT (8-phenyltheophylline) at adenosine A1 and A2 receptors in rat brain tissue. Biochem Pharmacol (1987) 0.81
CGS 20625, a novel pyrazolopyridine anxiolytic. J Pharmacol Exp Ther (1989) 0.80
Identification of a high-affinity anti-phosphoserine antibody for the development of a homogeneous fluorescence polarization assay of protein kinase C. J Biomol Screen (2000) 0.80
Fluorometer based multi-parameter analysis of phagocytic cell activation. Agents Actions (1987) 0.80
Interaction of L-glutamate and magnesium with phencyclidine recognition sites in rat brain: evidence for multiple affinity states of the phencyclidine/N-methyl-D-aspartate receptor complex. Mol Pharmacol (1987) 0.80
An antibody binding to human neutrophils demonstrates antigenic heterogeneity detected early in myeloid maturation which correlates with functional heterogeneity of mature neutrophils. J Immunol (1985) 0.80
Selective defect in human neutrophil superoxide anion generation elicited by the chemoattractant N-formylmethionylleucylphenylalanine in pregnancy. J Infect Dis (1983) 0.80
Increases in heart rate and blood pressure produced by microinjections of atrial natriuretic factor into the AV3V region of rat brain. Peptides (1986) 0.80
The role of osmotic pressure and membrane potential in K(+)-stimulated taurine release from cultured astrocytes and LRM55 cells. J Neurosci (1990) 0.80
High affinity interleukin-6 binding sites in bovine hypothalamus. Eur J Pharmacol (1991) 0.79
Comparison of antagonist and agonist binding to the leukotriene B4 receptor intact human polymorphonuclear neutrophils (PMN). J Pharmacol Exp Ther (1992) 0.79
Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo. J Immunol (1998) 0.79
Characterization of the binding of a novel nonxanthine adenosine antagonist radioligand, [3H]CGS 15943, to multiple affinity states of the adenosine A1 receptor in the rat cortex. Mol Pharmacol (1991) 0.79
Interactions of isamoltane (CGP 361A), an anxiolytic phenoxypropanolamine derivative, with 5-HT1 receptor subtypes in the rat brain. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.79
Platelet activating factor stimulates intracellular calcium transients in human neutrophils: involvement of endogenous 5-lipoxygenase products. J Leukoc Biol (1992) 0.78
Cardiovascular effects produced by microinjection of calcitonin gene-related peptide into the rat central amygdaloid nucleus. Peptides (1986) 0.78
Purification of rat liver mevalonate pyrophosphate decarboxylase. Prep Biochem Biotechnol (1996) 0.78
Polymorphonuclear leukocytes reduce cardiac function in vitro by release of H2O2. Am J Physiol (1990) 0.78
Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.78
Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin. Brain Res (1989) 0.78
Studies on the regulation of GABA synthesis: the interaction of adenine nucleotides and glutamate with brain glutamate decarboxylase. J Neurochem (1978) 0.78
Laboratory technics in rabies: Semple-type vaccine. Monogr Ser World Health Organ (1973) 0.77
Multiple states of the 5-hydroxytryptamine1 receptor as indicated by the effects of GTP on [3H]5-hydroxytryptamine binding in rat frontal cortex. Mol Pharmacol (1984) 0.77
Sesquiterpene-derived metabolites from the deep water marine sponge Poecillastra sollasi. J Nat Prod (1993) 0.77
ATP-dependent calcium transport in rat parotid basolateral membrane vesicles. Modulation by agents which elevate cyclic AMP. J Biol Chem (1986) 0.76
Characterization of an interleukin 6 cytokine family antagonist protein from a marine sponge, Callyspongia sp. J Biol Chem (1996) 0.76
A solid-phase assay for the determination of protein tyrosine kinase activity of c-src using scintillating microtitration plates. Anal Biochem (1996) 0.76
Aplysillin A, a thrombin receptor antagonist from the marine sponge Aplysina fistularis fulva. J Nat Prod (1995) 0.76
A marker of neutrophil heterogeneity reveals two forms of chronic myelogenous leukemia. Trans Assoc Am Physicians (1985) 0.75
An antibody to a subpopulation of neutrophils demonstrates antigenic heterogeneity which correlates with response heterogeneity. Trans Assoc Am Physicians (1984) 0.75
The unusual binding properties of the endothelin receptor antagonist CGS 27830 distinguishes receptor/agonist interactions. J Pharmacol Exp Ther (1996) 0.75
A case of two inversion (10) recombinants in a family. J Med Genet (1989) 0.75
Recombinant human C5a induces transcription but not translation of interleukin-1 beta mRNA in human monocytes. Res Immunol (1992) 0.75
Identification of a receptor-binding region in the core segment of the human anaphylatoxin C5a. J Med Chem (1994) 0.75
CGS 20625, a novel pyrazolopyridine with selective anxiolytic activity. Prog Clin Biol Res (1990) 0.75
Measurement of cdk4 kinase activity using an affinity peptide-tagging technology. Comb Chem High Throughput Screen (2000) 0.75
Measurement of membrane potential responses elicited from blood cells: effect of the dye/cell ratio and the presence of an intracellular calcium probe. Soc Gen Physiol Ser (1988) 0.75
Chronic administration of desipramine or nialamide decreases wet-dog shakes in rats produced by the TRH-analog MK-771. Brain Res (1987) 0.75
Synthesis, opioid receptor binding profile, and antinociceptive activity of 1-azaspiro[4.5]decan-10-yl amides. J Med Chem (1989) 0.75
Effect of chronic treatment with clorgyline on the relative concentration of specific proteins in the hippocampus and parietal cortex of the rat. Neuropharmacology (1986) 0.75
In vitro and in vivo evaluation of an endothelin inhibitor reveals novel K+ channel opening activity. Biochem Biophys Res Commun (1996) 0.75
Recombinant human C5a induces transcription but not translation of interleukin 1 beta mRNA in human monocytes. Lymphokine Cytokine Res (1992) 0.75
The discovery and characterization of an interleukin 6 cytokine family antagonist protein from a marine sponge, Callyspongia sp. Adv Exp Med Biol (2001) 0.75
An ex vivo method for studying inflammation in cynomolgus monkeys: analysis of interleukin-1 receptor antagonist. J Pharmacol Toxicol Methods (1996) 0.75
The N-methyl-D-aspartate receptor complex. J Recept Res (1988) 0.75
Cholecystokinin attenuates basal and drug-induced increases of limbic and striatal dopamine release. Brain Res (1988) 0.75